COVID-19 Vaccine Sponsors’ Pledge To Wait For Phase III Helps US FDA

The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.

Coronavirus
The coronavirus vaccine development pledge should not have been necessary, said Paul Offit of Children's Hospital of Philadelphia. • Source: Shutterstock

The pledge by multiple coronavirus vaccine developers to follow high development standards may alleviate as much pressure on the US Food and Drug Administration as it does on the individual companies pushing to make their products available.

Nine vaccine sponsor CEOs announced a non-binding commitment 8 September (see box) to always make the safety and well-being of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet